Holder evidence
50
SEC ownership of RxSight, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001111485.
Lead holder
BlackRock, Inc.
13D/G signal
BlackRock, Inc.
Latest evidence
31 Mar 2026
- CIK
- 0001111485
- Symbol
- RXST on Nasdaq
- Location
- Aliso Viejo, CA
- SEC evidence mix
- 13D/G, 13F, and 3/4/5
- Lead holder
- BlackRock, Inc.
- Latest large-stake holder
- BlackRock, Inc.
- Latest evidence date
- 31 Mar 2026
Issuer identity
Ownership snapshot
Ownership snapshot
Top shareholders of RxSight, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
BlackRock, Inc.
13D/G signal
BlackRock, Inc.
Evidence rows
50
Latest as of
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 5.8%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Rank 1 holder
BlackRock, Inc.
13D/G
13F
- Ownership
- 5.8%
- Position
- $21.52M
Rank 2 holder
MILLENNIUM MANAGEMENT LLC
13D/G
13F
- Ownership
- 5.4%
- Position
- $19.72M
Rank 3 holder
Artisan Partners Limited Partnership
13D/G
13F
- Ownership
- 5%
- Position
- $13.94M
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
5.8%
|
$21,515,668
2,393,289 shares
|
$0 | 30 Sep 2025 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
5.4%
|
$19,715,627
2,193,062 shares
|
-$3,757,056 | 30 Sep 2025 |
| Artisan Partners Limited Partnership |
13D/G
13F
Artisan Partners Asset Management Inc. · Company
|
5%
|
$13,937,291
2,058,684 shares
|
-$667,387 | 31 Mar 2026 |
| Divisadero Street Capital Management, LP |
13D/G
|
0.5%
|
$1,751,344
218,918 shares
|
-$18,500,824 | 30 Jun 2025 |
| BANK OF AMERICA CORP /DE/ |
13F
13D/G
Company
|
0.4%
from 13D/G
|
$7,453,841
1,210,039 shares
|
— | 31 Mar 2026 |
| LORD, ABBETT & CO. LLC |
13D/G
|
0%
|
$25,262
1,715 shares
|
$0 | 31 Dec 2024 |
| Jesse Anderson Corley |
3/4/5
Director
|
0.17%
|
$928,669
71,108 shares
|
— | 03 Jun 2025 |
| William J. Link PhD |
3/4/5
Director
|
0.14%
|
$771,884
59,103 shares
|
— | 03 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 31 May 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 21 reporting-owner rows connected to RxSight, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
21
Lead holder
RxSight I, LLC
Net 12M change
$0
Latest report
17 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| RxSight I, LLC | 10%+ Owner | $96,806,554 | Mixed | 03 Aug 2021 | ||
| Richard M. Wolfen | Director | $88,332,816 | Mixed | 03 Aug 2021 | ||
| Bruce C. Robertson | Director | $66,482,607 | Mixed | 03 Aug 2021 | ||
| Daniel Mark Schwartz | Director | $19,567,301 | Mixed | 03 Aug 2021 | ||
| RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | $10,265,312 | Mixed | 03 Aug 2021 | ||
| Eric Weinberg | Exhibit 24 - Power of Attorney Chief Business Development Officer | $4,697,521 | Mixed | 27 Feb 2026 | ||
| Jesse Anderson Corley | Director | $928,669 | Mixed | 03 Jun 2025 | ||
| William J. Link PhD | Director | $771,884 | Mixed | 03 Jun 2025 | ||
| Juliet Tammenoms Bakker | Director | $649,002 | Mixed | 03 Jun 2025 | ||
| PALMISANO ROBERT J | Director | $535,969 | Mixed | 03 Jun 2025 | ||
| Robert Keith Warner | Director | $535,969 | Mixed | 03 Jun 2025 | ||
| Julie Andrews | Director | $535,969 | Mixed | 03 Jun 2025 | ||
| Ilya Goldshleger | Chief Operating Officer | $490,047 | Median | 17 Apr 2026 | ||
| Tamara Fountain | Director | $464,217 | Mixed | 03 Jun 2025 | ||
| Raymond W. Cohen | Director | $285,344 | Mixed | 31 Jul 2025 | ||
| Shweta Maniar | Director | $236,843 | Mixed | 03 Jun 2025 | ||
| Shelley B. Thunen | Co-President and Chief Financial Officer | $166,403 | Mixed | 14 Apr 2025 | ||
| Scott Gaines | Chief Customer Officer | $112,993 | Mixed | 27 Feb 2026 | ||
| Mark Wilterding | Chief Financial Officer | $94,158 | Mixed | 28 Feb 2026 | ||
| Christopher Cox | Director | Mixed | 29 Jul 2021 |
Recent insider transactions for RxSight, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Ilya Goldshleger | RXST | Common Stock | Options Exercise | 19% | 12,489 | 78,180 | 17 Apr 2026 | Direct | ||
| Ilya Goldshleger | RXST | Stock Option (right to buy) | Options Exercise | -100% | -12,489 | 5 | 17 Apr 2026 | Direct | ||
| Mark Wilterding | RXST | Common Stock | Tax liability | -39.5% | -8,068 | 12,373 | 28 Feb 2026 | Direct | ||
| Mark Wilterding | RXST | Common Stock | Options Exercise | 20,441 | 20,441 | 28 Feb 2026 | Direct | |||
| Mark Wilterding | RXST | Restricted Stock Unit | Options Exercise | -12.5% | -20,441 | 143,087 | 28 Feb 2026 | Direct | ||
| Scott Gaines | RXST | Common Stock | Tax liability | -14.8% | -2,580 | 14,848 | 28 Feb 2026 | Direct | ||
| Scott Gaines | RXST | Common Stock | Options Exercise | 56.1% | 6,261 | 17,428 | 28 Feb 2026 | Direct | ||
| Scott Gaines | RXST | Restricted Stock Unit | Options Exercise | -72.2% | -6,261 | 2,414 | 28 Feb 2026 | Direct | ||
| Scott Gaines | RXST | Restricted Stock Unit | Award | 32,218 | 32,218 | 27 Feb 2026 | Direct | |||
| Ilya Goldshleger | RXST | Restricted Stock Unit | Award | 32,218 | 32,218 | 27 Feb 2026 | Direct | |||
| Eric Weinberg | RXST | Restricted Stock Unit | Award | 32,218 | 32,218 | 27 Feb 2026 | Direct | |||
| Ronald M. Kurtz MD | RXST | Restricted Stock Unit | Award | 80,545 | 80,545 | 27 Feb 2026 | Direct | |||
| Mark Wilterding | RXST | Restricted Stock Unit | Award | 163,528 | 163,528 | 12 Jan 2026 | Direct | |||
| Mark Wilterding | RXST | Stock Option (right to buy) | Award | 258,770 | 258,770 | 12 Jan 2026 | Direct | |||
| Ilya Goldshleger | RXST | Common Stock | Options Exercise | 55.5% | 23,445 | 65,691 | 25 Sep 2025 | Direct | ||
| Ilya Goldshleger | RXST | Stock Option (right to buy) | Options Exercise | -100% | -23,445 | 0 | 25 Sep 2025 | Direct | ||
| Raymond W. Cohen | RXST | Common Stock | Award | 35,668 | 35,668 | 31 Jul 2025 | Direct | |||
| William J. Link PhD | RXST | Common Stock | Award | 39.7% | 10,752 | 37,855 | 03 Jun 2025 | Direct | ||
| Tamara Fountain | RXST | Common Stock | Award | 43.4% | 10,752 | 35,545 | 03 Jun 2025 | Direct | ||
| Robert Keith Warner | RXST | Common Stock | Award | 35.5% | 10,752 | 41,039 | 03 Jun 2025 | Direct | ||
| Shweta Maniar | RXST | Common Stock | Award | 145.6% | 10,752 | 18,135 | 03 Jun 2025 | Direct | ||
| Palmisano Robert J | RXST | Common Stock | Award | 35.5% | 10,752 | 41,039 | 03 Jun 2025 | Direct | ||
| Julie Andrews | RXST | Common Stock | Award | 35.5% | 10,752 | 41,039 | 03 Jun 2025 | Direct | ||
| Bakker Juliet Tammenoms | RXST | Common Stock | Award | 28.8% | 10,752 | 48,146 | 03 Jun 2025 | Direct | ||
| Jesse Anderson Corley | RXST | Common Stock | Award | 28% | 10,752 | 49,190 | 03 Jun 2025 | Direct | ||
| Eric Weinberg | RXST | Common Stock | Options Exercise | 2558.2% | 188,002 | 195,351 | 02 Jun 2025 | Direct | ||
| Eric Weinberg | RXST | Stock Option (right to buy) | Options Exercise | -100% | -188,002 | 0 | 02 Jun 2025 | Direct |
* indicates a reported price that failed the local validity check.